ANI Pharmaceuticals (ANIP)
(Real Time Quote from BATS)
$62.02 USD
-0.17 (-0.27%)
Updated Jul 22, 2024 03:08 PM ET
2-Buy of 5 2
B Value A Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANIP 62.02 -0.17(-0.27%)
Will ANIP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ANIP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIP
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
ANIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why
Other News for ANIP
ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Buy Rating Affirmed: Strategic Acquisition Poised to Boost ANI Pharmaceuticals’ Revenue and Market Presence
ANI Pharmaceuticals price target raised by $7 at H.C. Wainwright, here's why